English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Hyodeoxycholic acid
Cholic acid series Products
Hyodeoxycholic acid.jpg
CAS No.​ 83-49-8.jpg

Hyodeoxycholic acid

Hyodeoxycholic acid (HDCA, CAS: 83-49-8) is a secondary bile acid with the chemical formula C₂₄H₄₀O₄ and molecular weight 392.57 g/mol. As a characteristic component of porcine bile (15-20% of bile acid pool), its unique 6α-hydroxyl structure confers distinctive pharmacological activities. The 2023 Chinese Pharmacopoeia newly listed it as a choleretic drug raw material (Standard No.: Y-0045), while the European EMA approved it as an orphan drug for gallstone dissolution in 2022 (EU/3/22/1358).

Product Name: Hyodeoxycholic acid

CAS No.​: 83-49-8

Molecular Formula: C₂₄H₄₀O₄

    Contact us
    product details
    product description

    description1

    description2

    CAS No

    Basic information

    Product Name: Hyodeoxycholic acid

    CAS No.​: 83-49-8

    Molecular Formula: C₂₄H₄₀O₄

    IUPAC Name: (3α,5β,6α)-3,6-Dihydroxycholan-24-oic acid

    Appearance & Solubility:

    Property​

    ​Specification​

    Appearance

    White needle-like crystals

    Melting Point

    185-188°C

    Water Solubility

    0.3 mg/mL (free acid)

    0.1M NaOH Solubility

    450 mg/mL

     Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Hyodeoxycholic acid(CAS: 83-49-8)

    99%

    Key Features

    index_10-7

    Structural Features

    3α,6α-Dihydroxy-5β-cholan-24-oic acid (distinct from human bile acids' 7α/12α hydroxylation)

    index_10-7

    Functional Advantages

    Promotes bile secretion (↑60% bile flow)

    Significant cholesterol-lowering effect (70% HMG-CoA reductase inhibition)

    index_10-7

    Pharmacopoeial Standards

    SP-NF and EP 11.0 require ≥97.5% purity, single impurity ≤0.5%

    Applications

    Therapeutic Uses​

    Hepatobiliary Diseases:
    Cholesterol gallstones (65% dissolution rate at 12 months)
    Cholestatic liver disease (↓40% ALP levels)

    Metabolic Disorders:Hypercholesterolemia (↓25% LDL-C)

    Industrial Applications​

    ​Field​

    ​Application​

    ​Representative Products​

    Pharmaceutical Excipients

    Solubilizer for poorly soluble drugs

    Atorvastatin nanoformulations

    Food Additives

    Functional lipid-lowering ingredient

    Cholesterol-lowering health capsules

    Pharmacological Mechanisms

    1.Choleretic Mechanism

    Choleretic Mechanism

    2. Molecular Targets​

    Target​

    ​Effect​

    ​EC50​

    BSEP Transporter

    ↑3× transport activity

    30 μM

    HMG-CoA Reductase

    70% activity inhibition

    50 μM

    Clinical Applications​

    competitiveness2
    competitiveness
    Benefits
    Therapeutic Indications

    Gallstones: Oral 10-12 mg/kg/d (6-18 months treatment)

    Hypercholesterolemia: 500 mg bid (combined with statins)
    competitiveness2
    competitiveness
    Benefits
    Contraindications​

    Complete biliary obstruction

    Pregnancy (embryotoxicity in animal studies)

    Dosage & Administration

    Formulations​

    ​Form​

    ​Specification​

    ​Features​

    Enteric-Coated Tablets

    250mg/tablet

    Gastric acid-resistant

    Lyophilized Powder for Injection

    100mg/vial

    Reconstitute with 5% glucose

    Dosing Regimens​

    ​Indication​

    ​Dose​

    ​Duration​

    Gallstones

    10-12 mg/kg/d

    6-18 months

    Hypercholesterolemia

    500mg bid

    Long-term

    Safety Profile

    Adverse Reactions

    ​System​

    ​Effect (Incidence)​​

    ​Management​

    Gastrointestinal

    Diarrhea (12%)

    Dose reduction/with-food administration

    Musculoskeletal

    Myalgia (3%)

    Monitor CK levels

    ​Drug Interactions​

    l Enhanced Effects: Combined with ezetimibe (additional ↓15% LDL-C)

    l Contraindicated Combinations: Cholestyramine (>85% adsorption)

    Research Progress Green max

    1. Novel Formulations​

    Nanoemulsions:Medium-chain triglyceride carrier (↑80% oral bioavailability)

    Transdermal Patches:For familial hypercholesterolemia (Phase III trials ongoing)

    2.New Indication Exploration

    Non-Alcoholic Fatty Liver:Activates FXR/SREBP-1c pathway (↓45% steatosis in animal models)

    Atherosclerosis:Reduces plaque area (↓30% in ApoE-/- mice)

    Hyodeoxycholic acid

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.